Difficulty: Medium
Average Score: 93%
Practice
A 13-year-old girl presents with acute myeloid leukemia (AML) and a WBC count of 120,000/mm3. Cytogenetics reveals a normal karyotype, and fluorescence in situ hybridization (FISH) tests for inv(16), t(8;21), t(15;17); 11q23 abnormalities; monosomy 7; and 5q deletion are negative. Molecular testing is negative for mutations in FLT3, NPM1, and CEBPA. She is treated with 10 days of daunorubicin, AraC, and gemtuzumab for induction therapy. On day 30, she recovers counts, and a bone marrow aspiration shows 2.2% leukemic blasts by flow cytometry. She receives a second course of treatment with daunorubicin and AraC, and her marrow is now in morphologic remission and is MRD-negative by flow cytometry. She has no HLA-matched siblings, but an unrelated donor search reveals a large number of potential matches. Which course of treatment is most likely to result in the best outcome?
Correct answer
C
Rationale
The correct answer is C. Performing a matched unrelated donor HSCT after one more course of intensification chemotherapy is the best course of treatment for the 13-year-old girl with AML. This is because although she achieved morphologic remission and MRD negativity after the second course of chemotherapy, HSCT provides the best chance for long-term disease control and potential cure in high-risk AML cases, especially in the absence of HLA-matched siblings. Autologous HSCT (choice B) is not preferred due to the high risk of relapse in AML. Giving two more courses of chemotherapy (choice A) may not provide additional benefit and can increase toxicity. Lastly, giving one more course of chemotherapy followed by maintenance chemotherapy (choice D) is not as effective as proceeding with HSCT to eliminate any residual disease and prevent relapse.